• 1. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 2. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 3. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 4. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 5. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555

Recent Advances in the Application of Ethyl 2-(1-aminocyclopropyl)acetate (CAS: 1211516-88-9) in Chemical Biology and Pharmaceutical Research

Ethyl 2-(1-aminocyclopropyl)acetate (CAS: 1211516-88-9) has emerged as a key intermediate in the synthesis of bioactive molecules, particularly in the development of novel pharmaceuticals. Recent studies highlight its utility in constructing cyclopropane-containing compounds, which are known for their unique pharmacological properties. This compound's structural motif, featuring a cyclopropylamine group, is increasingly recognized for its role in enhancing drug stability and target specificity.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the use of Ethyl 2-(1-aminocyclopropyl)acetate as a precursor in the synthesis of potent protease inhibitors. The research team employed a multi-step synthetic route, leveraging the compound's reactive amine group to introduce diverse pharmacophores. The resulting inhibitors showed nanomolar activity against SARS-CoV-2 main protease, suggesting potential applications in antiviral drug development.

In parallel, advancements in asymmetric synthesis have improved access to enantiomerically pure forms of this building block. A recent Organic Letters publication (2024) detailed a catalytic enantioselective method for producing (R)- and (S)-Ethyl 2-(1-aminocyclopropyl)acetate with >99% ee. This breakthrough addresses previous challenges in stereocontrol and opens new possibilities for chiral drug design.

The compound's metabolic stability has been systematically investigated in preclinical studies. Research presented at the 2024 American Chemical Society National Meeting revealed that derivatives containing the 1-aminocyclopropyl moiety exhibit superior resistance to cytochrome P450-mediated oxidation compared to their acyclic counterparts. This property is particularly valuable for improving oral bioavailability in candidate drugs.

Emerging applications extend beyond small molecule therapeutics. A 2024 Bioconjugate Chemistry report described the incorporation of Ethyl 2-(1-aminocyclopropyl)acetate into peptide-based drug delivery systems. The cyclopropyl ring's rigidity was found to enhance cellular uptake efficiency while minimizing off-target effects, suggesting utility in targeted cancer therapies.

Ongoing clinical trials (NCT05678921) are evaluating a cyclopropane-containing antidepressant whose synthesis pathway includes Ethyl 2-(1-aminocyclopropyl)acetate as a critical intermediate. Preliminary results indicate improved blood-brain barrier penetration compared to existing medications, with phase II data expected in Q4 2024.

Future research directions include exploring the compound's potential in PROTAC (proteolysis targeting chimera) development, where its structural features may facilitate optimal linker geometry. Computational modeling studies (J. Chem. Inf. Model., 2024) predict favorable ternary complex formation when incorporating this scaffold in degrader molecules targeting oncoproteins.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)